Cerebrotech Medical Systems, an innovative medical device company focused on the development of a portable brain bioimpedance monitor, today announced that board member Martin Dieck, an experienced entrepreneur with expertise in developing novel neurovascular solutions, will step up to executive chairman, effectively immediately. (Read More)
Innovation in health care takes longer and costs more than some investors are willing to take on. And beyond regulatory hurdles, health care institutions are cautious when considering new products and services, leading to slower adoption rates than in other industries. (Read More)
Ryan Macy has first-hand experience with the problems currently plaguing the U.S. in the post-acute care industry. His grandmother passed away from cancer during her stay at a Skilled Nursing Facility (SNF).
Following a hospital visit, many elderly patients require follow-up rehabilitative care, or “post-acute” care, which occurs in a separate facility like an SNF. But as a result of the country’s growing elderly population, it’s becoming increasingly difficult for clinicians to spend enough time with patients in these kinds of facilities. Read More
BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 200 Aortic Annuloplasty Device, the first and only annuloplasty device designed specifically for bicuspid aortic valve repair. With FDA clearance of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable is now able to offer U.S. surgeons a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency. (Read More)
Nashville, Tennessee-based Satchel Health has picked up another $1.5 million in funding, less than a year after its million-dollar angel round. Existing investor NueCura Partners contributed along with an unnamed group of local investors. This brings the company’s total funding to about $2.5 million. (Read More)
Cerebrotech Medical Systems, an innovative medical device company focused on the development of portable neurotechnology solutions, today reported results from a new study evaluating its proprietary VIPS™ technology for emergency stroke patients. The results of the study, VITAL, which are being presented at the 14th Annual Meeting of The Society of NeuroInterventional Surgery in Colorado Springs, CO, demonstrate that Cerebrotech’s non-invasive, visor-like neurological device can identify those patients with large vessel occlusion (LVO) strokes and large hemorrhagic strokes versus those with less urgent strokes, allowing for earlier intervention to prevent further brain damage. (Read More)
A new study describes how a minimally invasive system uses radiofrequency (RF) energy instead of open surgery to create hemodialysis arteriovenous fistulas (AVFs).
The TVA Medical (Austin, TX, USA) everlinQ endoAVF System utilizes two 6Fr magnetic catheters and a RF energy generator to create a consistent, hemodynamic AVF. The flexible magnetic catheters are first inserted into an artery and a vein in the arm. When in close proximity, the rare earth magnets in each catheter attract to each other, pulling the vessels together. After confirming alignment, a small burst of RF through the venous catheter opens an anastomosis between the artery and vein, creating the AVF. The catheters are then removed, leaving no surgical scar. (Read More)
GenomOncology today announced that UC San Francisco (UCSF) is now utilizing the GO Clinical Workbench for rapid analysis and reporting of results from the “UCSF500,” an advanced next-generation sequencing panel used by researchers and physicians at the UCSF Helen Diller Family Comprehensive Cancer Center for precision cancer diagnosis and treatment. (Read More)
TVA Medical, Inc. today announced the online publication of positive results from the Novel Endovascular Access Trial (NEAT) evaluating its everlinQTM endoAVF System. The 12-month data published online in the American Journal of Kidney Diseases (AJKD), the official journal of the National Kidney Foundation, demonstrate the potential benefit of the novel approach to create hemodialysis access as an alternative to traditional open surgery. (Read More)
-BioStable Science & Engineering, Inc. announced today the first commercial uses of the HAART 300 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Drs. Lawrence Wei, Vinay Badhwar and J. Scott Rankin of the WVU Heart and Vascular Institute were the collaborating surgeons for the procedures. The WVU Heart and Vascular Institute is the first of a select group of leading U.S. centers expected to participate in the limited launch of the HAART 300 device this year. (Read more)